Literature DB >> 1586986

The role of the stages of initiation and promotion in phenotypic diversity during hepatocarcinogenesis in the rat.

Y P Dragan1, H C Pitot.   

Abstract

Differences in the distribution of phenotypic alterations in initiated and promoted cell populations reflect both the dose and the action of the specific initiating agent, as well as the mechanism of action of the promoting agent. The use of multiple phenotypic markers to characterize AHF should allow further experimentation on the characteristics of promoting agents in hepatocarcinogenesis, especially their ability to promote separate populations of initiated cells, and on those characteristics of initiated cells that enable certain ones to survive and multiply in the specific environment provided by a promoting agent. Studies of promoting agents with differing mechanisms of action should further allow questions of reversibility, substitution and additivity of the actions of promoting agents to be addressed. The possibility that individual promoting agents do not enhance the growth of the entire population of initiated cells indicates that study of combinations of promoting agents is an important future direction of research. Therefore, information on the characteristics of promoting agents, singly and in combination, is necessary to assess more accurately the contribution of promoting agents to the carcinogenic risk for humans distinct from the effects of initiating agents and complete carcinogens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586986     DOI: 10.1093/carcin/13.5.739

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  18 in total

1.  Nuclear receptor CAR-regulated expression of the FAM84A gene during the development of mouse liver tumors.

Authors:  Hiroki Kamino; Yuichi Yamazaki; Kosuke Saito; Daichi Takizawa; Satoru Kakizaki; Rick Moore; Masahiko Negishi
Journal:  Int J Oncol       Date:  2011-03-17       Impact factor: 5.650

2.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

Review 3.  Hepatic neoplasia: reflections and ruminations.

Authors:  K Aterman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 4.  Stage-specific gene expression during hepatocarcinogenesis in the rat.

Authors:  H C Pitot
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Endotoxins enhance hepatocarcinogenesis induced by oral intake of thioacetamide in rats.

Authors:  Jin-Ming Yang; De-Wu Han; Chun-Ming Xie; Quan-Cheng Liang; Yuan-Chang Zhao; Xue-Hui Ma
Journal:  World J Gastroenterol       Date:  1998-04       Impact factor: 5.742

6.  Role of a novel CAR-induced gene, TUBA8, in hepatocellular carcinoma cell lines.

Authors:  Hiroki Kamino; Rick Moore; Masahiko Negishi
Journal:  Cancer Genet       Date:  2011-07

7.  Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.

Authors:  Yan-Tong Guo; Xi-Sheng Leng; Tao Li; Jing-Ming Zhao; Xi-Hou Lin
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

8.  Transgenic hepatocarcinogenesis in the rat.

Authors:  J R Hully; Y Su; J K Lohse; A E Griep; C A Sattler; M J Haas; Y Dragan; J Peterson; M Neveu; H C Pitot
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

Review 9.  Cell culture assays for chemicals with tumor-promoting or tumor-inhibiting activity based on the modulation of intercellular communication.

Authors:  I V Budunova; G M Williams
Journal:  Cell Biol Toxicol       Date:  1994-04       Impact factor: 6.691

Review 10.  Testing electromagnetic fields for potential carcinogenic activity: a critical review of animal models.

Authors:  J McCann; R Kavet; C N Rafferty
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.